When Korea Comes to Riyadh: A Biotech Bridge Worth Watching

On 24 August 2026 , a Korean Pavilion Webinar convened Korean biotechnology leaders ahead of the Riyadh Global Medical Biotechnology Summit (RGMBS 2026) — the Kingdom's flagship biotech gathering, held 14–16 September 2026 in Riyadh. RGMBS is organised by the Ministry of National Guard Health Affairs and hosted by KSAU-HS and KAIMRC , with the Ministry of Investment (Invest Saudi) as strategic partner and SDAIA among the backers.

The 2026 edition drew 100+ speakers and 70 country delegations across six tracks — AI in biotech, multi-omics and localization, biotech investment, immunology, bioengineering, and more.

Why a dedicated Korean pavilion, and why now. The webinar's stated purpose was to connect Korean innovators with Saudi Arabia's fast-maturing life-sciences ecosystem — to surface B2B and strategic partnerships, identify research, investment and commercialization opportunities, connect Korean innovation with Saudi ambitions, and build pathways beyond the summit itself.

It sits inside a bigger number: Saudi Arabia's National Biotechnology Strategy targets a $34.6bn non-oil GDP contribution by 2040 , backed by PIF capital, a modernising SFDA, and national institutions (KAIMRC, KSAU-HS, Lifera, SPIMACO) building the value chain from discovery to commercial scale. Korea — a genuine biotech power in biosimilars, diagnostics, cell therapy and AI drug discovery — is a logical partner.

The Korean participants — who came to the table

Twelve Korean organisations featured. Here's what each brings, verified where the public record allows and flagged where it's thin:

BASGENBIO — an AI and precision-medicine company (Seoul, founded 2018) built on the K-Biobank , a clinico-genomic cohort of ~156,000 Korean subjects. Its platforms (COCD, DEEPCT, TLBM) support biomarker discovery and clinical-trial simulation, and it already partners with Celltrion on genomics-based biomarker work. A natural fit for Saudi's genomics and precision-medicine agenda.

MVRIX — a Korean biotech active in vaccine/viral technologies, appearing on international biopharma partnering rosters. Relevant to Saudi vaccine-localization and infectious-disease priorities.

DewCell — a Korean cell-therapy/regenerative-medicine company (present on global biopharma partnering listings), aligned with the summit's cell-and-gene and immunology tracks.

Korea Institute of Toxicology (KIT) — a national government research institute for non-clinical safety/toxicology testing. Its value to Saudi is capability-building: preclinical safety science and the trial-enabling infrastructure the Kingdom is standing up.

CrossPoint Therapeutics · Preclina · KN Suncles · Digm Bio · Sci-Key Biotech · Gensionbio · MediaPlus · Medi N Research — the remaining Korean participants span therapeutics discovery, preclinical/CRO services, diagnostics and specialty biotech.

What this opens for MENA — the opportunities

1. Biosimilars and affordable oncology — the nearest-term prize. Korea is a global biosimilar leader, and MENA is already a buyer: Celltrion's six-biosimilar MENA deal with Hikma is live, and Korean pembrolizumab/daratumumab biosimilars are advancing through Phase 3. A pavilion like this is where the next such relationships germinate — and BASGENBIO's existing Celltrion link is a reminder that Korea's biosimilar champions travel with a wider ecosystem of data and diagnostics partners.

2. Precision medicine and genomics — a direct strategic match. Saudi Arabia is investing heavily in genomics and AI-driven discovery (KAIMRC, the Saudi Genome Program, HUMAIN). A biobank-and-AI company like BASGENBIO maps almost exactly onto that agenda — the opportunity is joint biobank build-out, biomarker discovery on Saudi cohorts, and clinical-trial simulation localised to regional populations. Genomic data is population-specific; MENA needs its own, and Korea has the platforms to help build it.

3. Preclinical and trial infrastructure — capability, not just product. With KIT (national toxicology) in the room, the opportunity extends beyond licensing molecules to transferring the enabling science — safety testing, CRO capability, trial networks. That's the harder, stickier, more valuable layer, and it aligns with Saudi's stated goal of building the full value chain, not just importing finished drugs.

4. Cell, gene and vaccine localization. DewCell (cell therapy) and MVRIX (vaccines) sit squarely in areas where Saudi entities (SPIMACO Bio, SVAX, Lifera) are actively localizing. The pattern our tracker keeps surfacing — Asian innovator supplies the science, Gulf champion supplies access and local manufacturing — extends naturally from China and India to Korea.

5. A new leg of the Asia→MENA corridor. MENA's inbound innovation has been dominated by China (Bio-Thera, Henlius, Junshi) and India (Aurobindo, Pinnacle). Korea is the sophisticated third source — stronger in regulated-market biosimilars and diagnostics than either. A structured Korea×Saudi channel diversifies MENA's supply of licensable innovation and strengthens its negotiating position.

The read for a MENA BD desk

This webinar is not a deal — it's a pipeline of potential deals , and the actionable move is to treat the pavilion roster as a shortlist. Prioritise the verified, strategically-aligned names first (BASGENBIO for genomics/AI; the biosimilar-adjacent players; KIT for capability transfer), confirm the niche participants' specifics directly, and open conversations now — while Saudi's National Biotechnology Strategy is actively funding exactly this kind of inbound partnership. The Kingdom has built the stage; events like this are where the counterparties audition.

Bottom line. Korea arriving in Riyadh is a signal that MENA's innovation-sourcing map is widening beyond China and India to include one of Asia's most regulated, biosimilar-strong ecosystems. For regional players, the opportunity is to be the local partner that turns a webinar introduction into a registered, localized, revenue-generating programme.